Tag Archives: biotech regulatory issues

Biologics & Biosimilars: What is the Science Telling Us?


Panelists from the varied backgrounds of academia, business and regulation agreed on the highest scientific standards of biosimilar regulation. Each panelist emphasized the need for the most stringent of standards in order to ensure patient safety and efficacy within the emerging biosimilars market. As Brian Liang, Executive Director of the Institute of Health Law Studies at California Western School of Law, summed it up, “the need in biosimilars is to focus on science, not cost. These are Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

2011 BIO International event spotlights expert feedback on regulatory strategy

Our good friend John Carroll, blogs on the free ranging discussion he will be hosting during the 2011 BIO International Convention, and tackling one of the most complex issues of the day for biopharma companies. You can send your questions to the panel of experts discussing the issues. In the meantime, you can also email John if there are any regulatory issues you are interested on discussing.

Events, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,